Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | -201.28% | -201.28% | 316.78% | 160.54% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -30.14% | -30.14% | 102.82% | 53.19% | |
| Operating Income | 30.14% | 30.14% | -102.82% | -53.19% | |
| Income Before Tax | 88.01% | 88.01% | -110.53% | -80.11% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 88.01% | 88.01% | -110.53% | -80.11% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 88.01% | 88.01% | -110.53% | -80.11% | |
| EBIT | 30.14% | 30.14% | -102.82% | -53.19% | |
| EBITDA | 29.88% | 28.86% | -113.79% | -61.18% | |
| EPS Basic | 94.27% | 94.27% | -110.50% | -79.84% | |
| Normalized Basic EPS | 79.74% | 79.74% | -92.12% | -53.84% | |
| EPS Diluted | 94.27% | 94.27% | -110.50% | -79.84% | |
| Normalized Diluted EPS | 79.74% | 79.74% | -92.12% | -53.84% | |
| Average Basic Shares Outstanding | 108.86% | 108.86% | 0.07% | 0.14% | |
| Average Diluted Shares Outstanding | 108.86% | 108.86% | 0.07% | 0.14% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |